These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15531040)

  • 1. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
    Olszewska W; Suezer Y; Sutter G; Openshaw PJ
    Vaccine; 2004 Nov; 23(2):215-21. PubMed ID: 15531040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
    Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
    Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
    Johnson TR; Varga SM; Braciale TJ; Graham BS
    J Virol; 2004 Aug; 78(16):8753-60. PubMed ID: 15280483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
    Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
    Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
    de Waal L; Wyatt LS; Yüksel S; van Amerongen G; Moss B; Niesters HG; Osterhaus AD; de Swart RL
    Vaccine; 2004 Feb; 22(8):923-6. PubMed ID: 15161069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
    Johnson TR; Teng MN; Collins PL; Graham BS
    J Virol; 2004 Jun; 78(11):6024-32. PubMed ID: 15141000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope.
    Zeng RH; Gong W; Fan CF; Wang YF; Mei XG
    Vaccine; 2006 Feb; 24(7):941-7. PubMed ID: 16159685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.
    Moghaddam A; Olszewska W; Wang B; Tregoning JS; Helson R; Sattentau QJ; Openshaw PJ
    Nat Med; 2006 Aug; 12(8):905-7. PubMed ID: 16862151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.
    Plotnicky-Gilquin H; Huss T; Aubry JP; Haeuw JF; Beck A; Bonnefoy JY; Nguyen TN; Power UF
    Virology; 1999 May; 258(1):128-40. PubMed ID: 10329575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocyte activity and cytokine expression in calves vaccinated with formalin-inactivated bovine respiratory syncytial virus prior to challenge.
    Woolums AR; Gunther RA; McArthur-Vaughan K; Anderson ML; Omlor A; Boyle GA; Friebertshauser KE; McInturff PS; Gershwin LJ
    Comp Immunol Microbiol Infect Dis; 2004 Jan; 27(1):57-74. PubMed ID: 14656542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
    Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.